Neuroprotection from complement-mediated inflammatory damage

Annals of the New York Academy of Sciences

Volumn 1035, Issue , 2004, Pages 147-164

  Kulkarni, Amod P ^a   Kellaway, Laurie A ^a   Lahiri, Debomoy K ^b   Kotwal, Girish J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Complement regulatory agents; Neurodegeneration; Neuroinflammation; Spinal cord injury; Vaccinia viral complement control protein

Indexed keywords

ALPHA INTERFERON; ANAPHYLATOXIN; ANTIOXIDANT; CANNABINOID; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOKINE; FLAVONOID; GAMMA INTERFERON; GLUTAMIC ACID; ICOSANOID; LEUKOTRIENE; NAFAMSTAT MESILATE; NEUROPROTECTIVE AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOL DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE C; S 32504; SCAVENGER; STEROID; SUPEROXIDE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN; VIRUS PROTEIN;

AGING; ALZHEIMER DISEASE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN INJURY; COMPLEMENT CLASSICAL PATHWAY; CONFERENCE PAPER; DEGENERATIVE DISEASE; DOWN SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; MACROPHAGE; MICROGLIA; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; SPINAL CORD INJURY;

LETHRINIDAE; VACCINIA; VACCINIA VIRUS;

EID: 14944373892     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1332.010     Document Type: Conference Paper

References (112)

1. DALY, J. & G.J. KOTWAL. 1998. Pro-inflammatory complement activation by the Aβ peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol. Aging 19: 619-627.
2. MCGEER, P.L. & E.G. MCGEER. 2004. Inflammation and neurodegeneration in Parkinson's disease. Parkinson Rel. Disorders 10: S3-S7.
3. EIKELENBOOM, P. et al. 2002. Neuroinflammation in Alzheimer's disease and prion disease. Glia. 40: 232-239.
4. HUNOT, S. & E.C. HIRSCH. 2003. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 53: S49-S60.
5. BRADL, M. & R. HOHLFELD. 2003. Molecular pathogenesis of neuroinflammation. J. Neurol. Neurosurg. Psychiatry 74: 1364-1370.
6. MULLER, H.D. et al. 2003. Inflammatory infiltrates in the spinal cord of patients with Guillain-Barre syndrome. Acta Neuropathol. 106: 509-517.
7. REYNOLDS, D.N. et al. 2003. Vaccinia virus complement control protein reduces neutrophil infiltration following spinal cord injury. Ann. N.Y. Acad. Sci. 1010: 534-539.
8. AISEN, P.S. et al. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. J. Am. Med. Assoc. 289: 2819-2826.
9. SCHARF, S. et al. 1999. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53:197-201.
10. MCGEER, P.L. & E.G. MCGEER. 1998. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzh. Dis. Assoc. Disord. 2: S1-S6.
11. MCGEER, P.L. et al. 1993. Microglia in degenerative neurological disease. Glia 7: 84-92.
12. SINGHRAO, S.K. et al. 1999. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159: 362-376.
13. GASQUE, P., M. FONTAINE & B.P. MORGAN. 1995. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154: 4726-4733.
14. NATAF, S. et al. 1999. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci. 22: 397-402.
15. NATAF, S. et al. 2001. Expression of the anaphylatoxin C5a receptor in the oligodendrocyte lineage. Brain Res. 894: 321-326.
16. DAVOUST, N. et al. 1999. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. 163: 6551-6556.
17. O'BARR, S.A. et al. 2001. Neuronal expression of a functional receptor for the C5a complement activation fragment. J. Immunol. 166: 4154-4162.
18. KREUTZBERG, G.W. 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19: 312-318.
19. DELEO, J.A. & R.P. YEZIERSKI. 2001. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90: 1-6.
20. LIAO, S.L. et al. 2001. Association of immune responses and ischemic brain infarction in rat. Neuroreport. 12: 1943-1947.
21. WERNER, P., D. PITT & C.S. RAINE. 2000. Glutamate excitotoxicity-a mechanism for axonal damage and oligodendrocyte death in multiple sclerosis? J. Neural Transm. Suppl. 60: 375-385.
22. STEIN, V.M. et al. 2004. Microglial cell activation in demyelinating canine distemper lesions. J. Neuroimmunol. 153: 122-131.
23. HICKEY, W.F. & H. KIMURA. 1988. Perivascular microglia are bone marrow derived and present antigen in vivo. Science 239: 290-292.
24. TIFFANY, H.L. et al. 2001. Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J. Biol. Chem. 276: 23645-23652.
25. BELL, M.D. et al. 1994. Upregulation of the macrophage scavenger receptor in response to different forms of injury in the CNS. J. Neurocytol. 23: 605-613.
26. CHRISTIE, R.H., M. FREEMAN & B.T. HYMAN. 1996. Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am. J. Pathol. 148: 399-403.
27. YANG, G.Y. et al. 1999. Tumor necrosis factor alpha expression produces increased blood-brain barrier permeability following temporary focal cerebral ischemia in mice. Mol. Brain. Res. 69: 135-143.
28. SINGHRAO, S.K. et al. 2000. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am. J. Pathol. 157: 905-918.
29. GASQUE, P. et al. 2002. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodelling activities. Mol. Neurobiol. 25: 1-17.
30. FONSECA, M.I. et al. 2004. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24: 6457-6465.
31. SHEN, Y. et al. 2001. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 305: 165-168.
32. HEAD, E. et al. 2001. Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down syndrome. Neurobiol. Dis. 8: 252-265.
33. HOLERS, V.M. & J.M. THURMAN. 2004. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol. Immunol. 41: 147-152.
34. VAN BEEK, J., K. ELWARD & P. GASQUE. 2003. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann. N.Y. Acad. Sci. 992: 56-71.
35. MORGAN, B.P. & P. GASQUE. 1996. Expression of complement in health and disease. Immunol. Today 17: 461-465.
36. SHEN, Y. & S. MERI. 2003. Yin and Yang: Complement activation and regulation in Alzheimer's disease. Prog. Neurobiol. 70: 463-472.
37. WEBSTER, S., C. GLABE & J. ROGERS. 1995. Multivalent binding of complement protein C1q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem. Biophys. Res. Commun. 217: 869-875.
38. JOHNS, T.G. & C.C. BERNARD. 1997. Binding of complement component C1q to myelin oligodendrocyte glycoprotein: a novel mechanism for regulating CNS inflammation. Mol. Immunol. 34: 33-38.
39. MULLER-EBERHARD, H.J. 1988. Molecular organisation and function of the complement system. Annu. Rev. Biochem. 57: 321-327.
40. PASINETTI, G.M. et al. 1996. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol. Dis. 3: 197-204.
41. MUKHERJEE, P. & G.M. PASINETTI. 2000. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J. Neuroimmunol. 105: 124-130.
42. MUKHERJEE, P. & G.M. PASINETTI. 2001. Complement anaphylatoxin C5a neuro-protects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J. Neurochem. 77: 43-49.
43. OSAKA, H. et al. 1999. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 90: 1-6.
44. VAN BEEK, J. et al. 2001. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 12: 289-293.
45. GERARD, C. & N.P. GERARD. 1994. C5a anaphylatoxin and its seven transmembrane receptor. Annu. Rev. Immunol. 12: 775-808.
46. DEL BALZO, U., M.J. POLLEY & R. LEVI. 1989. C3a-induced contraction of guinea pig ileum consists of two components: fast histamine-mediated and slow prostanoid-mediated. J. Pharmacol. Exp. Ther. 248: 1003-1009.
47. KAWATSU, R. et al. 1996. Conformationally biased analogs of human C5a mediate changes in vascular permeability. Pharmacol Exp. Ther. 278: 432-440.
48. GASQUE, P. et al. 1998. The receptor for complement anaphylatoxin c3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J. Immunol. 160: 3544-3554.
49. LIU, B, et al. 2002. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. N.Y. Acad. Sci. 962: 318-331.
50. BROWN, G.C. & A. BAL-PRICE. 2003. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 27: 325-355.
51. BAO, F. & D. LIU. 2002. Peroxynitrite generated in the rat spinal cord induces neuron death and neurological deficits. Neuroscience 115: 839-849.
52. KE, Z.J, & GE, GIBSON. 2004. Selective response of various brain cell types during neurodegeneration induced by mild impairment of oxidative metabolism. Neurochem. Intl. 45: 361-369.
53. NAKAMURA, Y. et al. 2003. Involvement of protein kinase C in glutamate release from cultured microglia. Brain Res. 962: 122-128.
54. ZWIRNER, J. et al. 1999. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies. Immunology 97: 166-172.
55. ACARIN, L. et al. 2002. Expression of inducible nitric oxide synthase and cyclooxygenase-2 after excitotoxic damage to the immature rat brain. J. Neurosci. Res. 68: 745-754.
56. INGLIS, V.I. et al. 2004. Neutrophils both reduce and increase permeability in a cell culture model of the blood-brain barrier. Brain Res. 998: 218-229.
57. TOGO, T., O. KATSUSE & E. ISEKI. 2004. Nitric oxide pathways in Alzheimer's disease and other neurodegenerative dementias. Neurol. Res. 26: 563-566.
58. THEOHARIDES, T.C. & D.E. COCHRANE. 2004. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J. Neuroimmunol. 146: 1-12.
59. WOOLHISER, M.R. et al. 2004. Activation of human mast cells by aggregated IgG through FcγRI: additive effects of C3a. Clin. Immunol. 110: 172-180.
60. WOOLLEY, D.E. & L.C. TETLOW. 2000. Mast cell activation and its relation to pro-inflammatory cytokine production in the rheumatoid lesion. Arth. Res. 2: 65-74.
61. FERRER, M., K. NAKAZAWA & A.P. KAPLAN. 1999. Complement dependence of histamine release in chronic urticaria. J. Allergy Clin. Immunol. 104: 169-172.
62. SAYAH, S. et al. 1999. Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mRNA expression. J. Neurochem. 72: 2426-2436.
63. PENKOWA, M. et al. 2003. Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide. J. Neurosci Res. 73: 481-496.
64. HEALES, S.J. et al. 2004. Neurodegeneration or neuroprotection: the pivotal role of astrocytes. Neurochem. Res. 29: 513-519.
65. WEISS, J.M. et al. 1998. Astrocyte-derived monocyte-chemoattractant protein-1 directs the transmigration of leukocytes across a model of the human blood-brain barrier. J. Immunol. 161: 6896-7903.
66. YANG, L.B. et al. 2000. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20: 7505-7509.
67. SHEN, Y. et al. 1997. Characterization of neuronal cell death induced by complement activation. Brain Res. Protocols 1: 186-194.
68. WURZNER, R. 2003. Deficiencies of the complement MAC II gene cluster (C6, C7, C9): is subtotal C6 deficiency of particular evolutionary benefit? Clin. Exp. Immunol. 133: 156-159.
69. LAHIRI, D.K. et al. 2003. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 4: 97-112.
70. FONSECA, M.I. et al. 2004. Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol Dis. 15: 40-46.
71. MCGEER, E.G. & P.L. MCGEER. 2003. Inflammatory processes in Alzheimer's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 27: 741-749.
72. STROHMEYER, R., Y. SHEN & J. ROGERS. 2000. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res. Mol. Brain. Res. 81: 7-18.
73. LAHIRI, D.K. et al. 2003. Role of cytokines in the gene expression of amyloid β-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J. Alz. Dis. 5: 81-90.
74. HEAD, E. et al. 2001. Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down syndrome Neurobiol. Dis. 8: 252-265.
75. SELLEBJERG, F. et al. 1998. Intrathecal activation of the complement system and disability in multiple sclerosis. J. Neurol. Sci. 157: 168-174.
76. SANDERS, M.E. et al. 1986. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J. Immunol. 136: 4456-4459.
77. PUTZU, G.A. et al. 2000. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J. Neurol. Sci. 174: 16-21.
78. MCGEER, P.L., K. YASOJIMA & E.G. MCGEER. 2001. Inflammation in Parkinson's disease. Adv. Neurol. 86: 83-89.
79. BELLANDER, B.M. et al. 2004. Activation of microglial cells and complement following traumatic injury in rat entorhinal-hippocampal slice cultures. J. Neurotrauma 21: 605-615.
80. XIONG, Z. et al. 2003. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J. Neurosci. 23: 955-960.
81. KOVACS, G.G. et al. 2004. Complement activation in human prion disease. Neurobiol. Dis. 15: 21-28.
82. SINGHRAO, S.K. et al. 1996. Role of complement in the aetiology of Pick's disease? J. Neuropathol. Exp. Neurol. 55: 578-593.
83. LI, J. et al. 2003. Peroxynitrite induces apoptosis in canine cerebral vascular muscle cells: possible relation to neurodegenerative diseases and strokes. Neurosci. Lett. 350: 173-177.
84. ROTILIO, G., K. AQUILANO & M.R. CIRIOLO. 2003. Interplay of Cu, Zn superoxide dismutase and nitric oxide synthase in neurodegenerative processes. IUBMB Life 55: 629-634.
85. CONSILVIO, C. et al. 2004. Neuroinflammation, COX-2, and ALS-a dual role? Exp. Neurol. 187: 1-10.
86. MAKRIDES, S.C. 1998. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50: 59-87.
87. HILTON, G.D. et al. 2004. Neuroprotective effects of estradiol in newborn female rat hippocampus. Brain Res. Dev. Brain Res. 150: 191-198.
88. GONZALEZ DENISELLE, M.C. et al. 2002. Basis of progesterone protection in spinal cord neurodegeneration. J. Steroid Biochem. Mol. Biol. 83: 199-209.
89. BRUCE-KELLER, A.J. et al. 2000. Antiinflammatory effects of estrogen on microglial activation. Endocrinology 141: 3646-3656.
90. AISEN, P.S. et al. 2000. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 54: 588-593; Comment Neurology 55: 1067.
91. AISEN, P.S. et al. 2000. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease cooperative study. Neurology 54: 588-593; Comment Neurology 55: 1067.
92. REICHMAN, W.E. 2000. Alzheimer's disease: clinical treatment options. Am. J. Manag. Care 6: S1125-S1132 [discussion: S1133-S1138].
93. KRISTIN, K.H. et al. 2003. The neuronal nitric oxide synthase inhibitor, TRIM, as a neuroprotective agent: effects in models of cerebral ischaemia using histological and magnetic resonance imaging techniques. Brain Res. 993: 42-53.
94. FLOYD, R.A. 2002. Nitrones as neuroprotectants and antiaging drugs. Ann. N.Y. Acad. Sci. 959: 321-329.
95. MIZUNO, T. et al. 2004. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 46: 404-411.
96. HARNETT, J.J. et al. 2004. Phenolic thiazoles as novel orally-active neuroprotective agents. Bioorganic Medicinal Chem. Lett. 14: 157-160.
97. BLAKE, A.D. 2004. Dipyridamole is neuroprotective for cultured rat embryonic cortical neurons. Biochem. Biophys. Res. Commun. 314: 501-504.
98. TOYODA, K. et al. 2004. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J. Neurol. Sci. 221: 11-17.
99. KATSUMATA, T. et al. 2003. Neuroprotective effect of NS-7, a novel Na and Ca channel blocker, in a focal ischemic model in the rat. Brain Res. 969: 168-174.
100. SARNE, Y. & O. KEREN. 2004. Are cannabinoid drugs neurotoxic or neuroprotective? Med. Hypotheses. 63: 187-192.
101. WYSS-CORAY, T. et al. 2002. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. 99: 10837-10842.
102. DE SIMONI, M.G. et al. 2004. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am. J. Pathol. 164: 1857-1863.
103. JHA, P. & G.J. KOTWAL. 2003. Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J. Biosci. 28: 265-271.
104. KOTWAL, G.J. & B. MOSS. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335: 176-178.
105. KOTWAL, G.J., S.N. ISSACS & R. MCKENZIE. 1990. Vaccinia virus major secretory protein inhibits the classical complement cascade. Science 250: 827-830.
106. MCKENZIE, R. et al. 1992. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166: 1245-1250.
107. SAHU, A. et al. 1998. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. J. Immunol. 160: 5596-5604.
108. KEELING, K.L. et al. 2000. Local neutrophil influx following lateral fluid percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system. J. Neuroimmunol. 105: 20-30.
109. AL-MOHANNA, F., R. PARHAR & G. J. KOTWAL. 2001. Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation 71: 796-801.
110. KOTWAL, G.J., D.K. LAHIRI & R. HICKS. 2002. Potential intervention by vaccinia virus complement control protein of the signals contributing to the progression of central nervous system injury to Alzheimer's disease. Ann. N.Y. Acad. Sci. 973: 317-322.
111. HICKS, R.H. et al. 2002. Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19: 705-714.
112. KOTWAL, G.J. 2000. Poxviral mimicry of complement and chemokine system components: what's the end game? Immunol. Today 21: 242-248.